We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
+$41.2M
Cap. Flow %
4.29%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 59.2%
2 Miscellaneous 33.43%
3 Technology 2.61%
4 Industrials 1.8%
5 Consumer Discretionary 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
26
DELISTED
Seagen Inc. Common Stock
SGEN
$7.07M 0.74%
+200,000
New +$6.82M
IWM icon
27
iShares Russell 2000 ETF
IWM
$76.9B
$6.98M 0.73%
56,100
+1,800
+3% +$217K
ARRY
28
DELISTED
Array Biopharma Inc
ARRY
$6.81M 0.71%
923,922
-50,000
-5% -$356K
BMY icon
29
Bristol-Myers Squibb
BMY
$128B
$6.45M 0.67%
100,000
-50,000
-33% -$3.13M
DYAX
30
DELISTED
DYAX CORPORATION
DYAX
$6.16M 0.64%
367,556
+50,000
+16% +$778K
AZN icon
31
AstraZeneca
AZN
$258B
$5.93M 0.62%
86,637
– –
CHKP icon
32
Check Point Software Technologies
CHKP
$13.9B
$5.9M 0.61%
+71,927
New +$5.81M
INSY
33
DELISTED
Insys Therapeutics, Inc.
INSY
$5.81M 0.61%
+200,000
New +$5.29M
BLCM
34
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.69M 0.59%
24,957
-8,194
-25% -$1.98M
CNCE
35
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.68M 0.59%
375,000
+225,000
+150% +$3.14M
AAPL icon
36
Apple
AAPL
$4.92T
$5.32M 0.55%
170,932
-40,280
-19% -$1.22M
ABUS icon
37
Arbutus Biopharma
ABUS
$1B
$5.21M 0.54%
298,486
+123,486
+71% +$2.53M
INSM icon
38
Insmed
INSM
$27.1B
$5.2M 0.54%
+250,000
New +$4.4M
KMDA icon
39
Kamada
KMDA
$500M
$5.17M 0.54%
293,727
– –
FWP
40
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.1M 0.53%
25,714
-2,857
-10% -$464K
TW
41
DELISTED
TOWERS WATSON & CO COM STK CL A (DE)
TW
$5.06M 0.53%
38,300
-4,050
-10% -$508K
VNDA icon
42
Vanda Pharmaceuticals
VNDA
$309M
$5.05M 0.53%
543,390
+175,000
+48% +$1.98M
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
$4.9M 0.51%
450,000
-100,000
-18% -$881K
RLYP
44
DELISTED
RELYPSA INC COM
RLYP
$4.87M 0.51%
135,000
+7,900
+6% +$285K
CPRX
45
DELISTED
Catalyst Pharmaceutical
CPRX
$4.76M 0.5%
1,100,000
+40,000
+4% +$144K
AGTC
46
DELISTED
Applied Genetic Technologies Corporation
AGTC
$4.7M 0.49%
235,124
+70,000
+42% +$1.57M
IPXL
47
DELISTED
Impax Laboratories, Inc.
IPXL
$4.69M 0.49%
+100,000
New +$3.98M
MDVN
48
DELISTED
MEDIVATION, INC.
MDVN
$4.66M 0.49%
72,230
-34,000
-32% -$1.95M
KYTH
49
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$4.51M 0.47%
+90,000
New +$3.78M
ASRT
50
DELISTED
Assertio
ASRT
$4.48M 0.47%
+3,333
New +$4.1M
1
2
3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $41.2M of net new capital in Q1 2015, opening 69 new positions and adding to 29 existing holdings. Its largest new stake was AbbVie: 407,000 shares worth $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 69% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Novartis, an estimated $33.6M trimmed.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.